Has Michael Brage, MD received payments from drug or device companies?

Yes. Drug and device makers reported $496,382 in general payments to Michael Brage, MD across 283 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Brage, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Brage, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Brage, MD

Orthopaedic Surgery · Seattle, WANPI 1194728709

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (50.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Paragon 28, Inc. accounts for 67.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $115,576 and has fallen 51.1% since, to $56,506 in 2025. Among orthopaedic surgery clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$496,382in general payments, 2019–2025

Across 283 payments — averaging $1754.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Paragon 28, Inc.$334K
Stryker$82K
Osteomed LLC$26K
Restor3d, Inc.$20K
Acumed LLC$14K
Integra Lifesciences Corporation$8K
plus $12K from 4 others

$23,529in research payments, 2019–2025

Across 21 payments — averaging $1120.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Integra Lifesciences Corporation$12K
Smith+Nephew$11K

What the payments were for

Royalty or licence$249,58950%
Consulting fees$196,01839%
Speaking & faculty fees$12,4183%
Travel & lodging$33,3217%
Food & beverage$5,0361%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Paragon 28, Inc.	141	$334,310
Stryker(2 entities)	75	$81,873
Osteomed LLC	11	$26,065
Restor3d, Inc.	16	$20,258
Acumed LLC	7	$13,850
Integra Lifesciences Corporation	16	$7,904
Ascension Orthopedics, Inc.	7	$6,938
Bioventus LLC	1	$4,713
Johnson & Johnson	8	$349
Axogen	1	$123

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Portfolio$193,582
Product Portfolio$84,046
INFINITY$69,004
INBONE$34,549
EXT-ExtremiLock Ankle$26,065
PROPHECY$24,774
INVISION$21,036
SALTO TALARIS TOTAL ANKLE PROSTHESIS$14,645
PANTA NAIL$14,145
TOTAL FOOT SYSTEM$14,145
CADENCE ANKLE REPLACEMENT SYSTEM$14,145
OsteoMed$13,850
AUGMENT INJECTABLE$13,358
ORTHOLOC 2 LAPIFUSE$10,350
APEX 3D$8,787
AUGMENT$5,559
Additive Orthopedics$2,951
PROstep$2,737
TRAUMA$782
HALLU-LOCK$728

How this compares

$496,382 in reported general payments places this provider in the 95th percentile of 495 orthopaedic surgery providers in Washington.

See all orthopaedic surgery providers in Washington →

Medicare billing

Part B allowed, 2024

$91,061

Medicare patients

228

Services billed

462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	14	$269
Meloxicam	18	$62

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Seattle

James PritchettSeattle$6.4M
James CrutcherSeattle$3.5M
Keith MayoSeattle$3.1M
Matthew SaltzmanSeattle$1.8M
Burt YaszaySeattle$1.3M
Sean ToomeySeattle$1.2M
Robert HartSeattle$942K
Jeffrey RohSeattle$604K
Daniel SchwartzSeattle$424K
Grant GarciaSeattle$367K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →